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Alzheimer’s disease (AD) is a progressive neurodegenerative dementia characterized by Ab deposi-
tion and neuroﬁbrillary tangles (NFTs) composed of hyperphosphorylated tau. Emerging evidence
shows that microRNAs (miRNAs) contribute to the pathogenesis of AD. Herein, we investigated
the role of miR-138, a brain enriched miRNA, which is increased in AD patients. We found that
miR-138 is increased in AD models, including N2a/APP and HEK293/tau cell lines. Overexpression
of miR-138 activates glycogen synthase kinase-3b (GSK-3b), and increases tau phosphorylation in
HEK293/tau cells. Furthermore, we conﬁrm that retinoic acid receptor alpha (RARA) is a direct target
of miR-138, and supplement of RARA substantially suppresses GSK-3b activity, and reduces tau
phosphorylation induced by miR-138. In conclusion, our data suggest that miR-138 promotes tau
phosphorylation by targeting the RARA/GSK-3b pathway.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Alzheimer’s disease (AD) is common dementia among elderly
people, which is characterized histologically by the appearance of
extracellular senile plaque (SP) formed by amyloid b (Ab) and
intracellular neuroﬁbrillary tangles (NFTs) resulting from hyper-
phosphorylated tau protein [1]. Accumulating evidence shows that
microRNAs (miRNAs) contribute to the pathogenesis of AD
[2–4].miRNAs are short non-coding RNAs whose sequences are
highly conserved [5,6]. miRNAs are essential regulators of genes
involved in a variety of biological processes. Many brain speciﬁc
and brain enriched miRNAs have been identiﬁed, and some of them
are associated with normal brain development and neuronal
differentiation [7,8]. Recent studies indicated that some miRNAs
regulated Ab production and tau phosphorylation, control synaptic
plasticity, or participate in the formation of memory [9–11]. The
expression patterns of miRNAs are altered in AD patients and AD
mouse models [12,13]. miR-138, a brain enriched miRNA increased
in AD patients [14], has been demonstrated to negatively regulatesynaptic plasticity. However, its role in the pathogenesis of AD
remains unclear.
In this study, we examined the expression of miR-138 in AD
model cell lines, and investigated the effects of miR-138 on tau
phosphorylation and the underling mechanisms. We found that
miR-138 was increased in AD cell models, and overexpression of
miR-138 increased tau phosphorylation. Furthermore, we identi-
ﬁed retinoic acid receptor alpha (RARA) was a direct target of
miR-138, and miR-138 induced tau hyperphosphorylation by
targeting RARA.
2. Materials and methods
2.1. Cell culture
N2a/APP cells which stably expressed human APP695, and
HEK293/tau cells which stably expressed human tau were main-
tained in DMEM, supplemented with 10% FBS, 0.2 g/L G418 (Invit-
rogen, Carlsbad, CA, USA) at 37 C with 5% CO2. Transfection was
performed using Lipofectamine 2000 reagent (Invitrogen, Carlsbad,
CA, USA). N2a/APP and HEK293/tau cells were kindly gifted by Prof.
Jianzhi Wang (Department of Pathophysiology, Tongji Medical
College, Huazhong University of Science and Technology. Key Lab-
oratory of Neurological Diseases of Education Ministry of China).
Fig. 1. Expression of miR-138 was increased in AD models. (A) Expression of
miR-138 in N2a/WT and N2a/APP cells were detected by qPCR. (B) Expression
of miR-138 in HEK293/WT and HEK293/tau cells were detected by qPCR.
⁄P < 0.05, ⁄⁄P < 0.01 compared with wild type cell line.
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The overexpression plasmid of miR-138 was purchased from
GeneCopoeia (Rockville, MD, USA). Overexpression construct of
RARA was generated by amplifying the CDS of RARA, and the PCR
fragment was subcloned into pcDNA4 (Invitrogen, Carlsbad, CA,
USA). 30-UTR of RARA containing the binding sites of miR-138:
TCACCACATCTTCATCACCAGCA (Position 314-336 of RARA 30-UTR)
was synthesized by Tsingke (Beijing, China), and inserted into psi-
CHECK2 (Promega, Madison, WI, USA) digested by XhoI and NotI.
Mutation was performed using a fast mutation kit from Agilent
(Brighton, MA USA).
2.3. RNA extraction and quantitative real-time PCR (qRT-PCR)
Total RNA was extracted by Trizol reagent (Invitrogen, Carlsbad,
CA, USA). MiRNAs were extracted using miRNA extraction and
cDNA synthesis kits from Tiangen (Beijing, China). The qRT-PCR
was performed on ABI Stepone Plus (Invitrogen, Carlsbad, CA,
USA) using SYBR Green mix (Takara, Tokyo, Japan). RARA primers:
sense 50-CTGCCCGGCTTCACCAC-30, antisense 50-CGAAGCCAGC
GTTGTGC-30. Primers for miR-138 and U6 were obtained from
GeneCopoeia (Rockville, MD, USA). The expression was determine
using 2DDCT method and normalized with b-actin or U6.
2.4. Luciferase activity assay
HEK293 cells were co-transfected with the miR-138 or the
control vector and wild-type (WT) or the mutant (Mut) of RARA
30-UTR. Cells were collected for luciferase activities 48 h after
transfection using luciferase activity reporter assay kit (Promega,
Madison, WI, USA).
2.5. Western blotting
Cells were homogenated with RIPA buffer (Beyotime, Shanghai,
China) on ice. Proteins were separated by 10% SDS–PAGE and
transferred to NC membranes, incubated with primary antibodies
overnight at 4 C. Then the membranes were further incubated
with secondary antibodies (LI-COR, Lincoln, NE, USA) for 1 h at
37 C and detected under the Odyssey Imaging System (LI-COR,
Lincoln, NE, USA).
2.6. Statistical analysis
Data were expressed as means ± S.D., analyzed using SPSS 12.0
(SPSS, Chicago, IL, USA) by Student’s t test or one-way ANOVA.
P < 0.05 was considered as statistically signiﬁcant.
3. Results
3.1. Expression of miR-138 was increased in AD models
The expression of miR-138 in several AD cell models was
detected. The expression of miR-138 was signiﬁcantly increased
in both N2a/APP (Fig. 1A) and HEK293/tau (Fig. 1B) cell lines. These
data indicate that miR-138 was elevated in AD models.
3.2. Overexpression of miR-138 promoted tau phosphorylation
One of the histological hallmark of AD is NFT, formed by hyper-
phosphorylated tau protein. We then investigated the effects of
miR-138 on tau phosphorylation. HEK293/tau cells were transfec-
ted with miR-138 overexpression plasmid or the scramble control,
and the phosphorylation level of tau at several sites were detected.We found that miR-138 increased the phosphorylation of tau at
Ser396 and Thr231 sites (Fig. 2A). The activities of kinase and phos-
phatase which functioned at these sites were examined, and we
revealed that the activity of Glycogen synthase kinase-3b (GSK-
3b) was activated, indicated by decreased phosphorylation of
Ser9 of GSK-3b, while the activity of phosphatase, protein phos-
phate 2A (PP2A) was not affected, indicated by phosphorylation
at Tyr307 of PP2A, which is inversely correlated with PP2A activity
(Fig. 2B). These data suggest that miR-138 increased tau phosphor-
ylation, and activated the activity of GSK-3b.
3.3. RARA was a direct target of miR-138
miRNAs function mainly by targeting their downstream targets.
TargetScan 6.2 (http://www.targetscan.org/) and miRanda (http://
www.microrna.org/) were used to search the potential target of
miR-138, and RARA contained potential binding sites of miR-138
(Fig. 3A). Luciferase activity assay showed that miR-138 signiﬁ-
cantly inhibited luciferase activity of the wild type (WT) but not
mutant (Mut) 30-UTR of RARA (Fig. 3B). Forced overexpression of
miR-138 signiﬁcantly suppressed RARA protein levels (Fig. 3C).
These data suggest that RARA was a target of miR-138.
3.4. miR-138 promoted tau phosphorylation by targeting RARA
We further studied whether miR-138 increased tau phosphory-
lation by targeting RARA. HEK293/tau cells were co-transfected
with miR-138 and RARA or the control vector, the results showed
that supplement of RARA by pcDNA4-RARA signiﬁcantly attenu-
ated the phosphorylation of tau (Fig. 4A) and GSK-3b activation
(Fig. 4B) induced by miR-138. These data indicate that miR-138
increased tau phosphorylation partially via targeting RARA.
4. Discussion
In the present study, we found that miR-138 was upregulated in
AD cell models. Forced overexpression of miR-138 induced GSK-3b
activation and tau phosphorylation. Furthermore, miR-138 bound
directly to the 30-UTR of RARA mRNA and reduced RARA
expression. Overexpression of RARA remarkably attenuated GSK-3b
activation and tau phosphorylation induced by miR-138.
Expression proﬁling of miRNAs has been studied in the brain,
cerebrospinal ﬂuid (CSF), and blood of AD patients and transgenic
models [14–16]. miR-138 has been known to regulate a variety of
essential biological processes, including dendritic spine morpho-
genesis, thermotolerance acquisition, and cardiac patterning
modulating during embryonic stage [17–19]. Siegel et al. reported
Fig. 2. Overexpression of miR-138 promoted tau phosphorylation. HEK293/tau
cells were transfected with miR-138 or the control vector. 48 h later, cells were
harvested for Western blotting. (A) Phosphorylation level at several sites of tau was
detected. (B) The phosphorylation of GSK-3b and PP2A was detected. These
antibodies, pS396, pS404, pT231 were used to detect the phosphorylation level at
Ser396, Ser404, and Thr231 sites of tau. Tau5 detected the total level of tau. S9 and
Y307 were used to detect the phosphorylation level at Ser9 and Tyr307 sites of
GSK-3b and PP2A, respectively. ⁄P < 0.05 compared with control vector.
Fig. 4. miR-138 promoted tau phosphorylation by targeting RARA. HEK293/tau
cells were co-transfected with miR-138 or the control vector and pcDNA4-RARA.
48 h later, cells were harvested for Western blotting. (A) Phosphorylation level at
several sites of tau was detected. (B) The phosphorylation of GSK-3b and PP2A was
detected. ⁄P < 0.05 compared with control vector. #P < 0.05 compared with miR-138
group.
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by targeting acyl protein thioesterase 1 (APT1), an enzyme which
regulated the palmitoylation status of proteins at the synapse
[17]. Furthermore, Liu et al. found that miR-138 acted as a novel
suppressor of axon regeneration via decreasing the expression of
SIRT1, an NAD-dependent histone deacetylase [20]. DysfunctionFig. 3. RARA was a direct target of miR-138. (A) RARA 30-UTR contained potential binding
vector and Wild type (WT) or mutant (Mut) RARA 30-UTR. 48 h later, cells were harveste
HEK293 cells were transfected with miR-138 or the control vector. 48 h later, cells were
compared with control vector.of synaptic plasticity was found in AD patients, and miR-138
may also contribute to this dysfunction [21]. Schröder et al. per-
formed genome-wide association studies (GWAS) in episodic and
working memory phenotypes, and they found that miR-138 might
be a potential regulator of episodic memory performance [22]. In
our study, for the ﬁrst time, we investigated the effects ofsites of miR-138. (B) HEK293 cells were co-transfected with miR-138 or the control
d and the dual luciferase activity were determined. RLU, relative luciferase unit. (C)
harvested and the protein level of RARA was detected by Western blotting. ⁄P < 0.05
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induce GSK-3b activation and tau phosphorylation at several sites,
while miR-138 did not affect the activity of PP2A, an essential
phosphatase in the regulation of tau phosphorylation. Our data
suggest that miR-138 may contribute to tau hyperphosphorylation
in AD.
The retinoic acid (RA) and RARA signaling pathway is essential
for normal brain maintenance, and previous studies revealed that
deﬁcit in this pathway was associated with AD [23]. RARA was
found to increase the expression of a disintegrin and metallopro-
tease 10 (ADAM10), suppress the activity of c-secretase, leading
to a reduction of Ab production [24,25]. Moreover, RARA could also
reduce tau phosphorylation by inhibiting GSK-3b activity [26]. In
this work, we found that miR-138 overexpression increased the
phosphorylation level of tau at Thr231, Ser396, and Ser404. The
kinase GSK-3b and phosphatase PP2A are two essential regulators
of tau phosphorylation at these sites [1]. We showed that GSK-3b
activity was increased after miR-138 overexpression, without
effect on PP2A. Moreover, we conﬁrmed that RARA was a target
of miR-138, and supplement of RARA substantially attenuated
these effects of miR-138. Our work expanded the role of RARA in
AD pathogenesis.
In conclusion, our data suggest that miR-138 may induce tau
hyperphosphorylation by targeting RARA/GSK-3b pathway.
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